June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Evaluation of Mobile Device Proficiency in Patients With Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Guillaume Normand
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Andres Emanuelli
    Emanuelli Research and Development Center, Puerto Rico
  • Kira Lin
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
    The University of Texas Health Science Center at Houston, Houston, Texas, United States
  • Onnisa Nanegrungsunk
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
    Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • Susan B Bressler
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Daniele Dolis
    Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
  • Lieve Convents
    Novartis Pharma NV/SA, Vilvoorde, Belgium
  • John Seaman
    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
  • Kang Yan
    Novartis Institutes for BioMedical Research Inc, Shanghai, China
  • Jayashree N sahni
    Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
  • Valda Murphy
    Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
  • Hani Salehi-Had
    Retina Associates of Southern California, California, United States
  • David Warrow
    Cumberland Valley Retina Consultants, Maryland, United States
  • Neil M Bressler
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Guillaume Normand Novartis, Code E (Employment); Andres Emanuelli Novartis, Novartis institute of Biomedical Research, Regeneron Pharmaceuticals, Roche/Genentech, Adverum Biotechnologies, Kodiak Science, Ophthea, Nanoscope Therapeutics, Code F (Financial Support); Kira Lin None; Onnisa Nanegrungsunk Roche, Code C (Consultant/Contractor), Allergan, Bayer, Novartis, Santen, Code R (Recipient); Susan Bressler Amgen, Code C (Consultant/Contractor), Grants to Johns Hopkins University from Bayer, Biocon, Biogen, Boehringer-Ingleheim Pharma GmbH & Co., EyePoint, Genentech (Roche), Mylan Inc, Notal Vision, Novartis, Regeneron Pharmaceuticals Inc, Bausch and Lomb, and Merck Sharpe and Dome, Code F (Financial Support); Daniele Dolis Novartis, Code E (Employment); Lieve Convents Novartis, Code E (Employment); John Seaman Novartis, Code E (Employment); Kang Yan Novartis, Code E (Employment); Jayashree sahni Novartis, Code E (Employment); Valda Murphy Novartis, Code E (Employment); Hani Salehi-Had None; David Warrow None; Neil Bressler Grants to Johns Hopkins University from Bayer, Biogen, Roche/Genentech, Novartis, Regeneron, Samsung Bioepis, Code F (Financial Support), Contract with the AMA as the Editor in Chief of JAMA Ophthalmology, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1749. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Guillaume Normand, Andres Emanuelli, Kira Lin, Onnisa Nanegrungsunk, Susan B Bressler, Daniele Dolis, Lieve Convents, John Seaman, Kang Yan, Jayashree N sahni, Valda Murphy, Hani Salehi-Had, David Warrow, Neil M Bressler; Evaluation of Mobile Device Proficiency in Patients With Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1749.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the proficiency of using mobile devices among study participants with neovascular age-related macular degeneration (nAMD).

Methods : This was an open, nonrandomized, multisite app feasibility study conducted in 105 participants (nAMD [n=57; without questionnaire data from one patient] and diabetic macular edema [n=48]) at 5 clinical centers in the US. At screening, participants completed a Mobile Device Proficiency Questionnaire-16 (MDPQ-16 from Roque and Boot, 2018), which evaluated mobile proficiency in certain tasks commonly performed with mobile devices.

Results : From the final results based on 56 participants with nAMD (mean age (SD), 73.6 (9.13) years; females, 28 (50.0%)), the mean total score (SD) for the MDPQ-16 was 31.2 (8.46) out of 40. The highest subscale score (4.6 out of 5) was recorded for knowledge of basic mobile device skills (navigation, keyboard), while the lowest subscale score (3.1 out of 5) was recorded for data transferring and storing skills (Table).

Conclusions : These results show less mobile proficiency in this patient population as compared to what was previously reported with young adults (average proficiency score: 38.4, n=39, 18-29 years old), and also highlight specific areas that need attention, while developing Digital Health Technologies for nAMD patients.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Mean scores of various mobile proficiency skills among 56 participants with neovascular AMD

Mean scores of various mobile proficiency skills among 56 participants with neovascular AMD

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×